Literature DB >> 32935393

Rescue of common exon-skipping mutations in cystic fibrosis with modified U1 snRNAs.

Stefano Donegà1, Malgorzata Ewa Rogalska1, Giulia Pianigiani1, Susana Igreja2, Margarida Duarte Amaral2, Franco Pagani1.   

Abstract

In cystic fibrosis (CF), the correction of splicing defects represents an interesting therapeutic approach to restore normal CFTR function. In this study, we focused on 10 common mutations/variants 711+3A>G/C, 711+5G>A, TG13T3, TG13T5, TG12T5, 1863C>T, 1898+3A>G, 2789+5G>A, and 3120G>A that induce skipping of the corresponding CFTR exons 5, 10, 13, 16, and 18. To rescue the splicing defects we tested, in a minigene assay, a panel of modified U1 small nuclear RNAs (snRNAs), named Exon Specific U1s (ExSpeU1s), that was engineered to bind to intronic sequences downstream of each defective exon. Using this approach, we show that all 10 splicing mutations analyzed are efficiently corrected by specific ExSpeU1s. Using complementary DNA-splicing competent minigenes, we also show that the ExspeU1-mediated splicing correction at the RNA level recovered the full-length CFTR protein for 1863C>T, 1898+3A>G, 2789+5G>A variants. In addition, detailed mutagenesis experiments performed on exon 13 led us to identify a novel intronic regulatory element involved in the ExSpeU1-mediated splicing rescue. These results provide a common strategy based on modified U1 snRNAs to correct exon skipping in a group of disease-causing CFTR mutations.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  RNA therapies; alternative splicing; personalized medicine; theranostics

Year:  2020        PMID: 32935393     DOI: 10.1002/humu.24116

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  2 in total

1.  OTC intron 4 variations mediate pathogenic splicing patterns caused by the c.386G>A mutation in humans and spfash mice, and govern susceptibility to RNA-based therapies.

Authors:  Claudia Sacchetto; Laura Peretto; Mirko Pinotti; Dario Balestra; Francisco Baralle; Iva Maestri; Francesca Tassi; Francesco Bernardi; Stan F J van de Graaf; Franco Pagani
Journal:  Mol Med       Date:  2021-12-14       Impact factor: 6.354

Review 2.  Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations.

Authors:  Craig S McIntosh; Gerald F Watts; Steve D Wilton; May T Aung-Htut
Journal:  Curr Opin Lipidol       Date:  2021-12-01       Impact factor: 4.776

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.